Board of Directors

Gail Maderis (Chairman)

Gail Maderis has over 25 years of leadership in biopharmaceutical companies and served as President and CEO of Antiva from July 2015 through April 2023. Under her leadership, Antiva advanced two molecules into clinical trials for HPV-related pre-cancers and completed four venture financings. From 2009 to 2015, Gail led BayBio, the industry organization representing and supporting Northern California’s life science community. From 2003 to 2009, Gail served as President and CEO of Five Prime Therapeutics, Inc. (FPRX), a protein discovery and development company focused on immuno-oncology. Prior to FivePrime, Gail held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). Gail also practiced management and strategy consulting with Bain & Co. Gail Maderis is Chairman of the board of DURECT Corporation (DRRX), and serves on the board of Valitor, Inc., as well as on the non-profit boards of BIO (Emerging Company and Health Sections), CLSI, The Termeer Foundation, and the University of California Berkeley Foundation Board of Trustees. She received a BS in business from UC Berkeley, and an MBA from Harvard Business School.

Brian Goodman

Partner, MPM BioImpact

Dr. Brian Goodman is a Partner at MPM BioImpact. He is responsible for leading investments and new company creation activities. He is a co-founder of Aktis Oncology and ReNAgade Therapeutics and serves as a member of the Board of Directors at Antiva Biosciences, and Orna Therapeutics. He has also played key leadership roles at portfolio companies during the early stages of development, including at Orna and ReNAgade leading Business Development and at Aktis Oncology as Chief Operations Officer and Chief Business Officer. Prior to joining MPM BioImpact, Brian co-founded Evelo Biosciences (NASDAQ: EVLO) and served as Head of Technology and Innovation. Before taking the operational role at Evelo, Brian was a Senior Associate at Flagship Pioneering. Brian has worked across a diverse span of science, drug discovery, development areas including the microbiome, extracellular vesicles, nonviral delivery, RNA medicines, and radiopharmaceuticals. He is an inventor on multiple patent applications. Brian holds a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School, and B.S. and B.A. degrees in biochemistry and economics, respectively, from Brandeis University.

Wende S. Hutton

General Partner, Canaan

Wende Hutton identifies, builds, and invests in companies that can change the practice of medicine by bringing novel drugs, technologies, and devices to market. She joined Canaan in 2004 and throughout her career she has partnered with founders to deliver more than a dozen of those innovations to patients. Her track record includes seven IPOs and six acquisitions. Wende currently sits on the boards of Antiva Biosciences, Glooko, Hyalex Orthopaedics, OncoResponse, and Qlaris Bio. Her prior investments include BiPar Sciences (acquired by Sanofi-Aventis), Chimerix (CMRX), Dermira (DERM), Labrys Biologics (acquired by Teva Pharmaceutical), and Transcend Medical (acquired by Alcon/Novartis). Wende was recognized among Fierce Biotech’s 2014 “Fierce 15” women in biotech.

Clifford M. Samuel

Principal, PCMS1 Consulting

Clifford Samuel has 30+ years of commercial leadership experience in the biopharmaceutical industry, with more than two decades at Gilead Sciences in leadership roles across sales, managed markets, and global commercial operations, including Senior Vice President, Global Patient Solutions, with responsibility for more than 140 countries. Propelled by his mission to ensure large-scale access to Gilead’s life-saving medicines, Clifford enabled the delivery of medicines to more than 18 million people in emerging markets, while increasing revenue by billions. He spearheaded Gilead’s entry into generic licensing agreements with companies in China, India and South Africa that created a competitive market for generic HIV and hepatitis B & C medicines. Clifford has been recognized for pioneering new and developing fields of technology, making major advancements in traditional fields of engineering, and developing and implementing innovative approaches to engineering education. A graduate of the New Jersey Institute of Technology (NJIT) with a BS in Mechanical Engineering, he received an Honorary PhD from his alma mater and sits as an NJIT Honor Program Board Member. He is also the recipient of an Edward F. Weston Medal for Professional Achievement and was inducted into the National Academy of Engineers in 2019. In addition to Antiva Biosciences he sits on the boards of the MTV Staying Alive Foundation, and serves as a business advisor to Siolta Therapeutics, Pardes Biosciences, and Karkinos Healthcare (India).

Florencia Segal

Partner, MPM BioImpact

Dr. Florencia Pereyra Segal is a Partner at MPM BioImpact. Florencia is an Infectious Diseases physician-scientist and drug development leader. Prior to joining MPM BioImpact, Florencia was the Global Head of Translational Medicine for Global Health at Novartis, during which time she and her team lead the early development of a broad portfolio, including small molecules and biologics for the treatment of viruses, bacteria, and parasites. Prior to her time in industry Florencia was a Principal Investigator leading translational and laboratory research focused on HIV immunology at the Ragon Institute of MGH, MIT and Harvard.

Florencia earned her M.D. with honors at the Universidad Central de Venezuela and completed her specialty Infectious Diseases and post-doctoral training at Brigham and Women’s and Massachusetts General Hospital. She remains a faculty member and associate physician at the Division of Infectious Diseases at Brigham and Women’s Hospital where she has practiced for over 15 years.

Jenny Yip

Managing Partner, Adjuvant Capital

Jenny Yip is currently a Managing Partner at Adjuvant Capital, a dedicated global health investment fund backed by the Bill and Melinda Gates Foundation, with a focus on serving those living in low- and middle-income resource areas. Prior to joining Adjuvant, Jenny was a Partner at the Gates Foundation Strategic Investment Fund where she represented the Foundation’s interests on numerous boards. Jenny serves on the boards of ChromaCode, 54gene, Evofem Biosciences and Excision Biotherapeutics and also serves on the Investment Advisory Committee at the Reproductive Health Investors’ Alliance and the Harvard School of Public Health Magazine. Jenny has worked in finance for more than 20 years beginning as an investment banker advising clients on mergers and acquisition at Goldman Sachs in Hong Kong, New York and San Francisco offices. Jenny graduated magna cum laude from Harvard University with an AB in History of Science.

Kristine Ball

President & CEO, Antiva Biosciences

Kristine Ball brings to Antiva over 20 years of executive experience in the biopharma industry. Kristine has held key roles in building multiple successful biopharma companies that developed FDA approved medicines. Kristine has also led numerous corporate transactions throughout her career including multiple IPOs, M&A transactions, pharmaceutical partnerships and other private and public financings. Prior to Antiva, Kristine served as Chief Executive Officer of Soteria, Inc. from 2020 to 2022, where she raised the company’s series A round of financing, recruited the management team and set the strategic direction of the company. From 2017 to 2022, Kristine served as Senior Vice President of Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., until the company’s merger with Foamix. At Menlo, Kristine was responsible for leading all non-R&D functions including strategic planning, corporate development, commercial, human resources, legal, finance and IT. She led Menlo’s initial public offering and the cross-functional team responsible for closing the merger with Foamix. Prior to Menlo, Kristine held executive finance positions at Relypsa, Inc. (acquired by Galenica), KAI Pharmaceuticals, Inc. (acquired by Amgen) and Exelixis, Inc. Kristine began her career in Ernst & Young’s life sciences audit practice. Kristine serves as a member of the board of directors of Atreca, Inc. and also served on the board of directors of Forty Seven Inc. prior to the company’s acquisition by Gilead. Kristine holds a B.S. from Babson College.